Clinical Trial Update: Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer

View source ↗

Summary

A completed clinical trial evaluating whether intratumoral heterogeneity on PSMA and FDG PET/CT imaging can predict invasion and prognosis in prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Jiequn Yu | Conditions: Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen | Status: COMPLETED